|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4201860A
(en)
|
1978-05-09 |
1980-05-06 |
Bristol-Myers Company |
Purine derivatives
|
|
US4415732A
(en)
|
1981-03-27 |
1983-11-15 |
University Patents, Inc. |
Phosphoramidite compounds and processes
|
|
US4426330A
(en)
|
1981-07-20 |
1984-01-17 |
Lipid Specialties, Inc. |
Synthetic phospholipid compounds
|
|
US5023243A
(en)
|
1981-10-23 |
1991-06-11 |
Molecular Biosystems, Inc. |
Oligonucleotide therapeutic agent and method of making same
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US5643889A
(en)
|
1984-07-11 |
1997-07-01 |
Temple University-Of The Commonwealth System Of Pennsylvania |
Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
|
|
US4992540A
(en)
|
1984-11-28 |
1991-02-12 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US4810646A
(en)
|
1984-11-28 |
1989-03-07 |
Massachusetts Institute Of Technology |
Glucan compositions and process for preparation thereof
|
|
US5028703A
(en)
|
1988-03-11 |
1991-07-02 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US5082936A
(en)
|
1984-11-28 |
1992-01-21 |
Massachusetts Institute Of Technology |
Glucan composition and process for preparation thereof
|
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
|
DE3529497A1
(de)
|
1985-08-17 |
1987-02-26 |
Boehringer Mannheim Gmbh |
N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
|
|
US4737323A
(en)
|
1986-02-13 |
1988-04-12 |
Liposome Technology, Inc. |
Liposome extrusion method
|
|
EP0260032B1
(en)
|
1986-09-08 |
1994-01-26 |
Ajinomoto Co., Inc. |
Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5264423A
(en)
|
1987-03-25 |
1993-11-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US5276019A
(en)
|
1987-03-25 |
1994-01-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Inhibitors for replication of retroviruses and for the expression of oncogene products
|
|
US4904582A
(en)
|
1987-06-11 |
1990-02-27 |
Synthetic Genetics |
Novel amphiphilic nucleic acid conjugates
|
|
US5188897A
(en)
|
1987-10-22 |
1993-02-23 |
Temple University Of The Commonwealth System Of Higher Education |
Encapsulated 2',5'-phosphorothioate oligoadenylates
|
|
US4924624A
(en)
|
1987-10-22 |
1990-05-15 |
Temple University-Of The Commonwealth System Of Higher Education |
2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
|
|
DE3738460A1
(de)
|
1987-11-12 |
1989-05-24 |
Max Planck Gesellschaft |
Modifizierte oligonukleotide
|
|
US5278302A
(en)
|
1988-05-26 |
1994-01-11 |
University Patents, Inc. |
Polynucleotide phosphorodithioates
|
|
US5750666A
(en)
|
1988-05-26 |
1998-05-12 |
Competitve Technologies, Inc. |
Polynucleotide phosphorodithioate compounds
|
|
ZA902710B
(en)
|
1989-05-22 |
1991-12-24 |
Univ Georgia Res Found |
Enzyme luminescence assay
|
|
US4958013A
(en)
|
1989-06-06 |
1990-09-18 |
Northwestern University |
Cholesteryl modified oligonucleotides
|
|
US5032401A
(en)
|
1989-06-15 |
1991-07-16 |
Alpha Beta Technology |
Glucan drug delivery system and adjuvant
|
|
ATE153856T1
(de)
|
1989-09-08 |
1997-06-15 |
Alpha Beta Technology |
Zusammensetzung zur stimulierung des immunsystems
|
|
JPH05503952A
(ja)
|
1989-09-08 |
1993-06-24 |
アルファ ベータ テクノロジー，インコーポレイティッド |
可溶性グルカン類の製造方法
|
|
US5591722A
(en)
|
1989-09-15 |
1997-01-07 |
Southern Research Institute |
2'-deoxy-4'-thioribonucleosides and their antiviral activity
|
|
US5495009A
(en)
|
1989-10-24 |
1996-02-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs containing thioformacetal linkages
|
|
US5264562A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences, Inc. |
Oligonucleotide analogs with novel linkages
|
|
DE69033495T2
(de)
|
1989-10-24 |
2000-07-20 |
Isis Pharmaceuticals, Inc. |
2'-modifizierte nukleotide
|
|
US5486603A
(en)
|
1990-01-08 |
1996-01-23 |
Gilead Sciences, Inc. |
Oligonucleotide having enhanced binding affinity
|
|
US5914396A
(en)
|
1990-01-11 |
1999-06-22 |
Isis Pharmaceuticals, Inc. |
2'-O-modified nucleosides and phosphoramidites
|
|
US5514786A
(en)
|
1990-01-11 |
1996-05-07 |
Isis Pharmaceuticals, Inc. |
Compositions for inhibiting RNA activity
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6153737A
(en)
|
1990-01-11 |
2000-11-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5670633A
(en)
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5578718A
(en)
|
1990-01-11 |
1996-11-26 |
Isis Pharmaceuticals, Inc. |
Thiol-derivatized nucleosides
|
|
US5646265A
(en)
|
1990-01-11 |
1997-07-08 |
Isis Pharmceuticals, Inc. |
Process for the preparation of 2'-O-alkyl purine phosphoramidites
|
|
US6395492B1
(en)
|
1990-01-11 |
2002-05-28 |
Isis Pharmaceuticals, Inc. |
Derivatized oligonucleotides having improved uptake and other properties
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US6358931B1
(en)
|
1990-01-11 |
2002-03-19 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulating RNA
|
|
AU7579991A
(en)
|
1990-02-20 |
1991-09-18 |
Gilead Sciences, Inc. |
Pseudonucleosides and pseudonucleotides and their polymers
|
|
US5658731A
(en)
|
1990-04-09 |
1997-08-19 |
Europaisches Laboratorium Fur Molekularbiologie |
2'-O-alkylnucleotides as well as polymers which contain such nucleotides
|
|
US5470967A
(en)
|
1990-04-10 |
1995-11-28 |
The Dupont Merck Pharmaceutical Company |
Oligonucleotide analogs with sulfamate linkages
|
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
|
US5151510A
(en)
|
1990-04-20 |
1992-09-29 |
Applied Biosystems, Inc. |
Method of synethesizing sulfurized oligonucleotide analogs
|
|
WO1991017424A1
(en)
|
1990-05-03 |
1991-11-14 |
Vical, Inc. |
Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
|
|
CA2040374C
(en)
|
1990-07-06 |
1998-06-16 |
Gunnar Rorstad |
Process for enhancing the resistance of aquatic animals to disease
|
|
CA2088258C
(en)
|
1990-07-27 |
2004-09-14 |
Phillip Dan Cook |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
|
US5623070A
(en)
|
1990-07-27 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Heteroatomic oligonucleoside linkages
|
|
US5602240A
(en)
|
1990-07-27 |
1997-02-11 |
Ciba Geigy Ag. |
Backbone modified oligonucleotide analogs
|
|
US5489677A
(en)
|
1990-07-27 |
1996-02-06 |
Isis Pharmaceuticals, Inc. |
Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
|
|
US5386023A
(en)
|
1990-07-27 |
1995-01-31 |
Isis Pharmaceuticals |
Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
|
|
CA2089376C
(en)
|
1990-08-13 |
2010-05-04 |
Phillip Dan Cook |
Sugar modified oligonucleotides that detect and modulate gene expression
|
|
US5512667A
(en)
|
1990-08-28 |
1996-04-30 |
Reed; Michael W. |
Trifunctional intermediates for preparing 3'-tailed oligonucleotides
|
|
EP0547142A1
(en)
|
1990-08-28 |
1993-06-23 |
Epoch Pharmaceuticals, Inc. |
Solid support synthesis of 3'-tailed oligonucleotides via a linking molecule
|
|
US5561225A
(en)
|
1990-09-19 |
1996-10-01 |
Southern Research Institute |
Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
|
|
JPH06505704A
(ja)
|
1990-09-20 |
1994-06-30 |
ギリアド サイエンシズ，インコーポレイテッド |
改変ヌクレオシド間結合
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
GB9022560D0
(en)
|
1990-10-17 |
1990-11-28 |
G B Biotechnology Limited |
Processing of waste
|
|
WO1994008003A1
(en)
|
1991-06-14 |
1994-04-14 |
Isis Pharmaceuticals, Inc. |
ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
|
|
US5419966A
(en)
|
1991-06-10 |
1995-05-30 |
Microprobe Corporation |
Solid support for synthesis of 3'-tailed oligonucleotides
|
|
US5214135A
(en)
|
1991-08-30 |
1993-05-25 |
Chemgenes Corporation |
N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
|
|
US5770209A
(en)
|
1991-08-30 |
1998-06-23 |
University Of South Florida |
Acceleration of wound healing using connective tissue growth factor
|
|
US7384634B2
(en)
|
1991-08-30 |
2008-06-10 |
University Of South Florida |
Connective tissue growth factor
|
|
US5525719A
(en)
|
1991-08-30 |
1996-06-11 |
Chemgenes Corporation |
N-protected-2'-O-methyl-and N-protected-3'-O-methyl-ribonucleosides and their phosphoramidite derivatives
|
|
US5607923A
(en)
|
1991-10-15 |
1997-03-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
|
|
US5599797A
(en)
|
1991-10-15 |
1997-02-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having phosphorothioate linkages of high chiral purity
|
|
US5661134A
(en)
|
1991-10-15 |
1997-08-26 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
|
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5359044A
(en)
|
1991-12-13 |
1994-10-25 |
Isis Pharmaceuticals |
Cyclobutyl oligonucleotide surrogates
|
|
US5856455A
(en)
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
|
NZ245720A
(en)
|
1992-01-22 |
1995-12-21 |
Hoechst Ag |
Oligonucleotide analogues; use as gene expression inhibitor or dna probe
|
|
US5633360A
(en)
|
1992-04-14 |
1997-05-27 |
Gilead Sciences, Inc. |
Oligonucleotide analogs capable of passive cell membrane permeation
|
|
US5817781A
(en)
|
1992-06-01 |
1998-10-06 |
Gilead Sciences, Inc. |
Modified internucleoside linkages (II)
|
|
EP0577558A2
(de)
|
1992-07-01 |
1994-01-05 |
Ciba-Geigy Ag |
Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
|
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
JP3351476B2
(ja)
|
1993-01-22 |
2002-11-25 |
三菱化学株式会社 |
リン脂質誘導体及びそれを含有するリポソーム
|
|
WO1994022891A1
(en)
|
1993-03-31 |
1994-10-13 |
Sterling Winthrop Inc. |
Oligonucleotides with amide linkages replacing phosphodiester linkages
|
|
WO1994023028A2
(en)
|
1993-03-31 |
1994-10-13 |
Hybridon, Inc. |
Modified oligonucleotides having improved anti-influenza activity
|
|
FR2705099B1
(fr)
|
1993-05-12 |
1995-08-04 |
Centre Nat Rech Scient |
Oligonucléotides phosphorothioates triesters et procédé de préparation.
|
|
EP0626387B1
(de)
|
1993-05-12 |
1999-03-10 |
Novartis AG |
Nukleoside und Oligonukleotide mit 2'-Ethergruppen
|
|
US6015886A
(en)
|
1993-05-24 |
2000-01-18 |
Chemgenes Corporation |
Oligonucleotide phosphate esters
|
|
US5580972A
(en)
|
1993-06-14 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
Purine nucleoside modifications by palladium catalyzed methods
|
|
US5428149A
(en)
|
1993-06-14 |
1995-06-27 |
Washington State University Research Foundation |
Method for palladium catalyzed carbon-carbon coulping and products
|
|
US5534259A
(en)
|
1993-07-08 |
1996-07-09 |
Liposome Technology, Inc. |
Polymer compound and coated particle composition
|
|
US5532130A
(en)
|
1993-07-20 |
1996-07-02 |
Dyad Pharmaceutical Corporation |
Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
|
|
US5417978A
(en)
|
1993-07-29 |
1995-05-23 |
Board Of Regents, The University Of Texas System |
Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
|
|
US5614621A
(en)
|
1993-07-29 |
1997-03-25 |
Isis Pharmaceuticals, Inc. |
Process for preparing oligonucleotides using silyl-containing diamino phosphorous reagents
|
|
WO1995006731A2
(en)
|
1993-09-02 |
1995-03-09 |
Ribozyme Pharmaceuticals, Inc. |
Non-nucleotide containing enzymatic nucleic acid
|
|
DE69433036T2
(de)
|
1993-09-03 |
2004-05-27 |
Isis Pharmaceuticals, Inc., Carlsbad |
Aminoderivatisierte nukleoside und oligonukleoside
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
EP0725788B1
(en)
|
1993-10-27 |
1998-12-16 |
Ribozyme Pharmaceuticals, Inc. |
2'-amido and 2'-peptido modified oligonucleotides
|
|
AU687492B2
(en)
|
1993-11-16 |
1998-02-26 |
Genta Incorporated |
Synthetic oligomers having phosphonate internucleosidyl linkages of undefined chirality mixed with non-phosphonate internucleosidyl linkages
|
|
WO1995013827A1
(en)
|
1993-11-19 |
1995-05-26 |
The University Of Sydney |
A method for preventing or controlling cataract
|
|
US5652359A
(en)
|
1993-12-02 |
1997-07-29 |
Epoch Pharmaceuticals, Inc. |
Oligonucleotides containing n-methyl thiolated bases having antiviral activity
|
|
EP0796109A1
(en)
|
1993-12-17 |
1997-09-24 |
The Ohio State University |
Antisense oligonucleotides to suppress eicosanoid formation
|
|
DE69500618D1
(de)
|
1994-02-18 |
1997-10-02 |
Hybridon Inc |
Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
|
|
US5646126A
(en)
|
1994-02-28 |
1997-07-08 |
Epoch Pharmaceuticals |
Sterol modified oligonucleotide duplexes having anticancer activity
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5651981A
(en)
|
1994-03-29 |
1997-07-29 |
Northwestern University |
Cationic phospholipids for transfection
|
|
US5625050A
(en)
|
1994-03-31 |
1997-04-29 |
Amgen Inc. |
Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
|
|
US5777153A
(en)
|
1994-07-08 |
1998-07-07 |
Gilead Sciences, Inc. |
Cationic lipids
|
|
US5580731A
(en)
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
|
US5591721A
(en)
|
1994-10-25 |
1997-01-07 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US5681940A
(en)
|
1994-11-02 |
1997-10-28 |
Icn Pharmaceuticals |
Sugar modified nucleosides and oligonucleotides
|
|
US5767099A
(en)
|
1994-12-09 |
1998-06-16 |
Genzyme Corporation |
Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules
|
|
US5948767A
(en)
|
1994-12-09 |
1999-09-07 |
Genzyme Corporation |
Cationic amphiphile/DNA complexes
|
|
US5716824A
(en)
|
1995-04-20 |
1998-02-10 |
Ribozyme Pharmaceuticals, Inc. |
2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
|
|
US5830430A
(en)
|
1995-02-21 |
1998-11-03 |
Imarx Pharmaceutical Corp. |
Cationic lipids and the use thereof
|
|
AUPN166195A0
(en)
|
1995-03-13 |
1995-04-06 |
Norvet Research Pty Limited |
Process for glucan extraction
|
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
|
WO1996040961A1
(en)
|
1995-06-07 |
1996-12-19 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
|
US5851548A
(en)
|
1995-06-07 |
1998-12-22 |
Gen-Probe Incorporated |
Liposomes containing cationic lipids and vitamin D
|
|
DE69634084T2
(de)
|
1995-06-07 |
2005-12-08 |
Inex Pharmaceuticals Corp. |
Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
|
|
US6221911B1
(en)
|
1995-06-07 |
2001-04-24 |
Karo Bio Ab |
Uses for thyroid hormone compounds or thyroid hormone-like compounds
|
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
|
AUPN398295A0
(en)
|
1995-07-05 |
1995-07-27 |
Carlton And United Breweries Limited |
Chemical compounds and processes for their production
|
|
US5734041A
(en)
|
1995-10-20 |
1998-03-31 |
Mcgill University |
Preparation of chiral phosphorothioate oligomers
|
|
US5705621A
(en)
|
1995-11-17 |
1998-01-06 |
Isis Pharmaceuticals, Inc. |
Oligomeric phosphite, phosphodiester, Phosphorothioate and phosphorodithioate compounds and intermediates for preparing same
|
|
US5684143A
(en)
|
1996-02-21 |
1997-11-04 |
Lynx Therapeutics, Inc. |
Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
|
|
US6331617B1
(en)
|
1996-03-21 |
2001-12-18 |
University Of Iowa Research Foundation |
Positively charged oligonucleotides as regulators of gene expression
|
|
US6444806B1
(en)
|
1996-04-30 |
2002-09-03 |
Hisamitsu Pharmaceutical Co., Inc. |
Conjugates and methods of forming conjugates of oligonucleotides and carbohydrates
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US5789416B1
(en)
|
1996-08-27 |
1999-10-05 |
Cv Therapeutics Inc |
N6 mono heterocyclic substituted adenosine derivatives
|
|
US6111085A
(en)
|
1996-09-13 |
2000-08-29 |
Isis Pharmaceuticals, Inc. |
Carbamate-derivatized nucleosides and oligonucleosides
|
|
US5849902A
(en)
|
1996-09-26 |
1998-12-15 |
Oligos Etc. Inc. |
Three component chimeric antisense oligonucleotides
|
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
|
US7504493B2
(en)
|
1997-01-23 |
2009-03-17 |
The John Hopkins University |
Characterization of the yeast transcriptome
|
|
DE69841002D1
(de)
|
1997-05-14 |
2009-09-03 |
Univ British Columbia |
Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
|
|
AU7499198A
(en)
|
1997-05-21 |
1998-12-11 |
Johns Hopkins University, The |
Gene expression profiles in normal and cancer cells
|
|
ES2279580T3
(es)
|
1997-09-15 |
2007-08-16 |
Genetic Immunity, Llc |
Composiciones para administrar genes a celulas de la piel que presentan antigenos.
|
|
US6028183A
(en)
|
1997-11-07 |
2000-02-22 |
Gilead Sciences, Inc. |
Pyrimidine derivatives and oligonucleotides containing same
|
|
JP4135318B2
(ja)
|
1997-12-15 |
2008-08-20 |
アステラス製薬株式会社 |
新規なピリミジン−５−カルボキサミド誘導体
|
|
US6506559B1
(en)
|
1997-12-23 |
2003-01-14 |
Carnegie Institute Of Washington |
Genetic inhibition by double-stranded RNA
|
|
WO1999033878A1
(en)
|
1997-12-25 |
1999-07-08 |
Japan Tobacco Inc. |
Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
|
|
US6020475A
(en)
|
1998-02-10 |
2000-02-01 |
Isis Pharmeuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
EP1071753A2
(en)
|
1998-04-20 |
2001-01-31 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
|
US20040241845A1
(en)
|
1998-05-22 |
2004-12-02 |
Luc Desgroseillers |
Mammalian staufen and use thereof
|
|
US6242589B1
(en)
|
1998-07-14 |
2001-06-05 |
Isis Pharmaceuticals, Inc. |
Phosphorothioate oligonucleotides having modified internucleoside linkages
|
|
US6277967B1
(en)
|
1998-07-14 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
|
|
US6271358B1
(en)
|
1998-07-27 |
2001-08-07 |
Isis Pharmaceuticals, Inc. |
RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
|
|
US6043352A
(en)
|
1998-08-07 |
2000-03-28 |
Isis Pharmaceuticals, Inc. |
2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
|
|
US20040009938A1
(en)
|
1998-08-07 |
2004-01-15 |
Muthiah Manoharan |
Methods of enhancing renal uptake of oligonucleotides
|
|
US6344323B1
(en)
*
|
1998-09-16 |
2002-02-05 |
Vitagenix, Inc. |
Compositions and methods for inhibiting cox-2 expression and treating cox-2 associated disorders by using cox-2 antisense oligonucleotides
|
|
US6020483A
(en)
|
1998-09-25 |
2000-02-01 |
Nexstar Pharmaceuticals, Inc. |
Nucleoside modifications by palladium catalyzed methods
|
|
US6475490B1
(en)
|
1998-10-19 |
2002-11-05 |
Fordham University |
Compositions and methods for promoting tissue repair using heat shock proteins
|
|
US6492129B1
(en)
|
1998-12-14 |
2002-12-10 |
University Of Miami |
Fragments of connective tissue growth factor that induce extracellular matrix synthesis, collagen synthesis and/or myofibroblast differentiation
|
|
US7115390B1
(en)
|
1998-12-14 |
2006-10-03 |
Fibrogen, Inc. |
Connective tissue growth factor fragments and methods and uses thereof
|
|
US6455586B1
(en)
|
1998-12-15 |
2002-09-24 |
Leonard L. Kaplan |
Topical immunomodulating compositions for treatment of aids, Hepatitis B & C, other infectious diseases, and cancer
|
|
PT1146908E
(pt)
|
1999-01-27 |
2005-10-31 |
David Dr Becker |
Formulacoes que contem nucleotidos de anti-sentido para conexinas
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
US6465628B1
(en)
|
1999-02-04 |
2002-10-15 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligomeric compounds
|
|
NZ513402A
(en)
|
1999-02-12 |
2003-06-30 |
Sankyo Co |
Novel nucleosides and oligonucleotide analogues
|
|
US6207819B1
(en)
|
1999-02-12 |
2001-03-27 |
Isis Pharmaceuticals, Inc. |
Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
|
|
US6121437A
(en)
|
1999-03-16 |
2000-09-19 |
Isis Pharmaceuticals, Inc. |
Phosphate and thiophosphate protecting groups
|
|
US6706491B1
(en)
|
1999-04-09 |
2004-03-16 |
The Board Of Trustees Of The University Of Illinois |
Reagents and methods for identifying and modulating expression of genes regulated by p21
|
|
US6492497B1
(en)
|
1999-04-30 |
2002-12-10 |
Cambridge Antibody Technology Limited |
Specific binding members for TGFbeta1
|
|
CA2378512A1
(en)
|
1999-06-16 |
2000-12-21 |
The Johns Hopkins University |
Characterization of the yeast transcriptome
|
|
US6593466B1
(en)
|
1999-07-07 |
2003-07-15 |
Isis Pharmaceuticals, Inc. |
Guanidinium functionalized nucleotides and precursors thereof
|
|
GB9925459D0
(en)
|
1999-10-27 |
1999-12-29 |
Plant Bioscience Ltd |
Gene silencing
|
|
US8017742B2
(en)
|
1999-11-10 |
2011-09-13 |
Japan Science And Technology Agency |
Gene carrier
|
|
JP2001206899A
(ja)
|
1999-11-18 |
2001-07-31 |
Japan Tobacco Inc |
ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
|
|
US20040072785A1
(en)
|
1999-11-23 |
2004-04-15 |
Wolff Jon A. |
Intravascular delivery of non-viral nucleic acid
|
|
US7829693B2
(en)
|
1999-11-24 |
2010-11-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a target gene
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
US7098030B2
(en)
|
1999-12-31 |
2006-08-29 |
Mirus Bio Corporation |
Polyampholytes for delivering polyions to a cell
|
|
US20050032733A1
(en)
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
|
AU2001245793A1
(en)
|
2000-03-16 |
2001-09-24 |
Cold Spring Harbor Laboratory |
Methods and compositions for rna interference
|
|
EP1309726B2
(en)
|
2000-03-30 |
2018-10-03 |
Whitehead Institute For Biomedical Research |
Rna sequence-specific mediators of rna interference
|
|
US7108721B2
(en)
|
2000-05-11 |
2006-09-19 |
Massachusetts Institute Of Technology |
Tissue regrafting
|
|
WO2001085941A2
(en)
|
2000-05-11 |
2001-11-15 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Myc targets
|
|
EP1311277A4
(en)
|
2000-07-18 |
2004-08-25 |
Joslin Diabetes Center Inc |
METHODS OF FIBROSIS MODULATION
|
|
JP5154728B2
(ja)
|
2000-07-24 |
2013-02-27 |
クレニツキー・ファーマシューティカルズ，インコーポレイテッド |
神経栄養活性を有する置換５−アルキニルピリミジン
|
|
WO2002010217A2
(en)
|
2000-08-02 |
2002-02-07 |
The Johns Hopkins University |
Endothelial cell expression patterns
|
|
US20040054166A1
(en)
|
2000-08-03 |
2004-03-18 |
Martin Sauter |
Isolation of glucan particles and uses thereof
|
|
US6794137B2
(en)
|
2000-09-08 |
2004-09-21 |
New York University |
Gene markers useful for detecting skin damage in response to ultraviolet radiation
|
|
US6753321B2
(en)
|
2000-09-15 |
2004-06-22 |
Genvec, Inc. |
Method of modulating neovascularization
|
|
US6476003B1
(en)
|
2000-11-06 |
2002-11-05 |
Immusonic, Inc. |
Method for preparing small particle size glucan in a dry material
|
|
US20020132788A1
(en)
|
2000-11-06 |
2002-09-19 |
David Lewis |
Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
|
|
RU2322500C2
(ru)
|
2000-12-01 |
2008-04-20 |
Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. |
Малые молекулы рнк, опосредующие интерференцию рнк
|
|
FR2818642B1
(fr)
|
2000-12-26 |
2005-07-15 |
Hoechst Marion Roussel Inc |
Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
|
|
CA2433680A1
(en)
|
2000-12-28 |
2002-08-01 |
Gregory M Arndt |
Double-stranded rna-mediated gene suppression
|
|
DE10100127A1
(de)
|
2001-01-03 |
2002-10-02 |
Henkel Kgaa |
Verfahren zur Bestimmung der Homeostase der Haut
|
|
DE10100121A1
(de)
|
2001-01-03 |
2002-08-01 |
Henkel Kgaa |
Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro
|
|
US7044945B2
(en)
|
2001-03-30 |
2006-05-16 |
Sand Bruce J |
Prevention of regression in thermal ciliary muscle tendinoplasty
|
|
CA2443995C
(en)
|
2001-04-11 |
2014-06-03 |
The Johns Hopkins University |
Endothelial cell expression patterns
|
|
WO2002087541A1
(en)
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
|
US20060211642A1
(en)
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
|
CA2526831C
(en)
|
2001-05-18 |
2012-07-31 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
|
|
US20070032441A1
(en)
|
2001-05-18 |
2007-02-08 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
|
|
WO2003070884A2
(en)
|
2002-02-20 |
2003-08-28 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
US20050233997A1
(en)
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
|
DE10131458A1
(de)
|
2001-06-29 |
2003-01-09 |
Aventis Pharma Gmbh |
Verfahren zur Identifizierung von Verbindungen zur Therapie von Alterungsprozessen des Herz-Kreislauf Systems
|
|
US20030158403A1
(en)
|
2001-07-03 |
2003-08-21 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant chimeric oligonucleotides
|
|
DE10133858A1
(de)
|
2001-07-12 |
2003-02-06 |
Aventis Pharma Gmbh |
Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
|
|
WO2003012052A2
(en)
|
2001-07-30 |
2003-02-13 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Specific inhibition of gene expression by small double stranded rnas
|
|
AU2002326939A1
(en)
|
2001-09-18 |
2003-04-01 |
Fibrogen, Inc. |
Methods of assaying connective tissue growth factor
|
|
US7786094B2
(en)
|
2001-10-09 |
2010-08-31 |
Biopolymer Engineering, Inc. |
Use of beta-glucans against biological warfare weapons and pathogens including anthrax
|
|
WO2003035083A1
(de)
|
2001-10-26 |
2003-05-01 |
Ribopharma Ag |
Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz
|
|
JP2005506087A
(ja)
|
2001-10-26 |
2005-03-03 |
リボファーマ アーゲー |
プラス鎖ｒｎａウイルスによる感染症を処置するための２本鎖リボ核酸の使用
|
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
|
AU2002368202B2
(en)
|
2001-11-02 |
2008-06-05 |
Insert Therapeutics, Inc |
Methods and compositions for therapeutic use of RNA interference
|
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
|
AU2002366641A1
(en)
|
2001-12-11 |
2003-06-23 |
Fibrogen, Inc. |
Methods for inhibiting ocular processes
|
|
US20060009409A1
(en)
|
2002-02-01 |
2006-01-12 |
Woolf Tod M |
Double-stranded oligonucleotides
|
|
DK1470144T3
(da)
|
2002-02-01 |
2009-04-06 |
Univ Mcgill |
Oligonukleotider omfattende alternerende segmenter og anvendelser deraf
|
|
EP2221377B2
(en)
|
2002-02-01 |
2017-05-17 |
Life Technologies Corporation |
Oligonucleotide compositions with enhanced efficiency
|
|
WO2003064621A2
(en)
|
2002-02-01 |
2003-08-07 |
Ambion, Inc. |
HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
|
|
US6923833B2
(en)
|
2002-04-09 |
2005-08-02 |
Ray C. Wasielewski |
Biologically reabsorbable acetabular constraining components and materials for use with a hip replacement prosthesis and bioreabsorbable materials to augment hip replacement stability and function
|
|
WO2003099840A1
(en)
|
2002-05-24 |
2003-12-04 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having modified nucleoside units
|
|
FR2840217B1
(fr)
|
2002-06-03 |
2005-06-24 |
Oreal |
Compositions cosmetiques comprenant au moins un oligonucleotide d'arn double brin (dsrna)et leurs utilisations
|
|
US20040022707A1
(en)
*
|
2002-06-05 |
2004-02-05 |
Exxonmobil Research And Engineering Company |
Oxidation of NOx's with sodium chlorite in combination with a thermal NOx removal process
|
|
ES2280826T5
(es)
|
2002-08-05 |
2017-08-03 |
Silence Therapeutics Gmbh |
Nuevas formas adicionales de moléculas de ARN de interferencia
|
|
DE10238298A1
(de)
|
2002-08-21 |
2004-03-04 |
Beiersdorf Ag |
Verwendung von Antisense-Oligonucleotiden zur Behandlung von degenerativen Hauterscheinungen
|
|
WO2004027030A2
(en)
|
2002-09-18 |
2004-04-01 |
Isis Pharmaceuticals, Inc. |
Efficient reduction of target rna’s by single- and double-stranded oligomeric compounds
|
|
ATE513843T1
(de)
|
2002-09-25 |
2011-07-15 |
Univ Massachusetts |
Abstellen von genen in vivo durch chemischmodifizierte und stabile sirna
|
|
AU2003284323A1
(en)
|
2002-10-18 |
2004-05-04 |
Alnylam Pharmaceuticals Inc |
Double-stranded rna structures and constructs, and methods for generating and using the same
|
|
US7309361B2
(en)
|
2002-10-23 |
2007-12-18 |
Wasielewski Ray C |
Biologic modular tibial and femoral component augments for use with total knee arthroplasty
|
|
JP2006517916A
(ja)
|
2002-10-30 |
2006-08-03 |
ザ シービーアール インスティテュート フォー バイオメディカル リサーチ インコーポレーティッド |
Ｒｎａ干渉物質を用いてアポトーシス関連疾患を治療および予防する方法
|
|
ES2334125T3
(es)
|
2002-11-04 |
2010-03-05 |
University Of Massachusetts |
Interferencia de arn especifico de alelos.
|
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
|
WO2006006948A2
(en)
*
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
DK2284266T3
(da)
|
2002-11-14 |
2014-01-13 |
Thermo Fisher Scient Biosciences Inc |
sIRNA-MOLEKYLE MOD TP53
|
|
US7655785B1
(en)
|
2002-11-14 |
2010-02-02 |
Rosetta Genomics Ltd. |
Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
|
|
DE10254214A1
(de)
|
2002-11-20 |
2004-06-09 |
Beiersdorf Ag |
Oligoribonukleotide zur Behandlung von degenerativen Hauterscheinungen durch RNA-Interferenz
|
|
US7217807B2
(en)
|
2002-11-26 |
2007-05-15 |
Rosetta Genomics Ltd |
Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
|
|
US20040204377A1
(en)
|
2002-11-26 |
2004-10-14 |
University Of Massachusetts |
Delivery of siRNAs
|
|
WO2004065600A2
(en)
|
2003-01-17 |
2004-08-05 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Rna interference by palindromic or modified rna molecules
|
|
DE10302421A1
(de)
|
2003-01-21 |
2004-07-29 |
Ribopharma Ag |
Doppelsträngige Ribonukleinsäure mit verbesserter Wirksamkeit
|
|
EP1589931A2
(en)
|
2003-02-05 |
2005-11-02 |
University of Massachusetts |
RNAi TARGETING OF VIRUSES
|
|
US20040162235A1
(en)
|
2003-02-18 |
2004-08-19 |
Trubetskoy Vladimir S. |
Delivery of siRNA to cells using polyampholytes
|
|
US20040167090A1
(en)
|
2003-02-21 |
2004-08-26 |
Monahan Sean D. |
Covalent modification of RNA for in vitro and in vivo delivery
|
|
EP1604012A2
(en)
|
2003-03-05 |
2005-12-14 |
The Board of Trustees of The Leland Stanford Junior University |
METHODS AND COMPOSITIONS FOR SELECTIVE RNAi MEDIATED INHIBITION OF GENE EXPRESSION IN MAMMAL CELLS
|
|
EP3450559A1
(en)
|
2003-03-07 |
2019-03-06 |
Alnylam Pharmaceuticals, Inc. |
Therapeutic compositions
|
|
EP1604014A4
(en)
|
2003-03-20 |
2008-03-26 |
Dana Farber Cancer Inst Inc |
GENE EXPRESSION IN BREAST CANCER
|
|
JP4605799B2
(ja)
|
2003-04-02 |
2011-01-05 |
ダーマコン， インコーポレイテッド |
Ｒｎａ干渉において使用するための修飾ポリヌクレオチド
|
|
ES2702942T3
(es)
|
2003-04-17 |
2019-03-06 |
Alnylam Pharmaceuticals Inc |
Agentes de ARNi modificados
|
|
WO2004099372A2
(en)
|
2003-05-01 |
2004-11-18 |
University Of Florida |
Anti-scarring ribozymes and methods
|
|
US20060178327A1
(en)
|
2003-05-30 |
2006-08-10 |
Yeung Wah Hin A |
Inhibition of gene expression by delivery of specially selected double stranded or other forms of small interfering RNA precursors enabling the formation and function of small interfering RNA in vivo and in vitro
|
|
US7750144B2
(en)
|
2003-06-02 |
2010-07-06 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of RNA silencing
|
|
ATE485394T1
(de)
|
2003-06-02 |
2010-11-15 |
Univ Massachusetts |
Verfahren und zusammensetzungen zur verbesserung der wirksamkeit und spezifität von fnai
|
|
US7405274B2
(en)
|
2003-06-04 |
2008-07-29 |
Fibrogen, Inc. |
Connective tissue growth factor antibodies
|
|
EP2336317B1
(en)
|
2003-06-13 |
2019-09-11 |
Alnylam Europe AG |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
SG190613A1
(en)
|
2003-07-16 |
2013-06-28 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering rna
|
|
WO2005019430A2
(en)
|
2003-08-22 |
2005-03-03 |
Research Development Foundation |
In vitro selection of aptamer beacons
|
|
US20050118625A1
(en)
|
2003-10-02 |
2005-06-02 |
Mounts William M. |
Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
|
|
EP1687410A4
(en)
|
2003-10-07 |
2008-04-09 |
Isis Pharmaceuticals Inc |
ANTISENSE OLIGONUCLEOTIDE OPTIMIZED FOR KIDNEY TARGETING
|
|
BRPI0416920A
(pt)
|
2003-11-24 |
2007-01-23 |
Canji Inc |
redução de cicatriz dérmica
|
|
CA2550058C
(en)
*
|
2003-12-19 |
2016-07-12 |
Antisense Pharma Gmbh |
Pharmaceutical composition comprising a tgf-beta2 antisense oligonucleotide and a chemotherapeutic
|
|
WO2005070970A1
(en)
|
2004-01-16 |
2005-08-04 |
Fibrogen, Inc. |
Connective tissue growth factor signaling
|
|
US20070269889A1
(en)
|
2004-02-06 |
2007-11-22 |
Dharmacon, Inc. |
Stabilized siRNAs as transfection controls and silencing reagents
|
|
WO2005079533A2
(en)
|
2004-02-17 |
2005-09-01 |
University Of Massachusetts |
Methods and compositions for mediating gene silencing
|
|
US20080071068A1
(en)
|
2004-02-20 |
2008-03-20 |
Hideki Oba |
Cytoplasmic Localization Dna and Rna
|
|
WO2005085443A2
(en)
|
2004-03-01 |
2005-09-15 |
Massachusetts Institute Of Technology |
Rnai-based therapeutics for allergic rhinitis and asthma
|
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
|
US20080300147A1
(en)
|
2004-03-26 |
2008-12-04 |
Nasser Chegini |
Detection and Treatment of Fibrotic Disorders
|
|
KR101147147B1
(ko)
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
US20050265957A1
(en)
|
2004-04-08 |
2005-12-01 |
Monahan Sean D |
Polymerized formamides for use in delivery of compounds to cells
|
|
EP1773998A2
(en)
|
2004-04-20 |
2007-04-18 |
Nastech Pharmaceutical Company Inc. |
Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells
|
|
US8168600B2
(en)
|
2004-04-23 |
2012-05-01 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
|
US7687616B1
(en)
|
2004-05-14 |
2010-03-30 |
Rosetta Genomics Ltd |
Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
|
|
ES2434415T3
(es)
|
2004-05-20 |
2013-12-16 |
Eden Research Plc |
Composiciones que contienen una partícula hueca de glucano o una partícula de pared celular encapsulando un componente de terpeno, métodos para su fabricación y utilización.
|
|
CA2568735A1
(en)
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
|
AU2005252273B2
(en)
|
2004-06-07 |
2011-04-28 |
Arbutus Biopharma Corporation |
Lipid encapsulated interfering RNA
|
|
US7740861B2
(en)
|
2004-06-16 |
2010-06-22 |
University Of Massachusetts |
Drug delivery product and methods
|
|
WO2006021817A2
(en)
|
2004-08-23 |
2006-03-02 |
Sylentis S.A.U. |
Treatment of eye disorders characterized by an elevated introacular pressure by sirnas
|
|
US20060211766A1
(en)
|
2004-09-30 |
2006-09-21 |
Kaplan Leonard L |
Gelled immunomodulating topical compositions and a method of treating warts and other human papilloma virus skin infections
|
|
EP1796732B1
(en)
|
2004-10-01 |
2013-10-30 |
Novartis Vaccines and Diagnostics, Inc. |
Modified small interfering rna molecules and methods of use
|
|
US20100069620A1
(en)
|
2004-12-02 |
2010-03-18 |
Rxi Pharmaceuticals Corp. |
Novel compositions of chemically modified small interfering rna
|
|
US7910561B2
(en)
|
2004-12-15 |
2011-03-22 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
TWI386225B
(zh)
*
|
2004-12-23 |
2013-02-21 |
Alcon Inc |
用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
|
|
US20060142228A1
(en)
|
2004-12-23 |
2006-06-29 |
Ambion, Inc. |
Methods and compositions concerning siRNA's as mediators of RNA interference
|
|
US20060171943A1
(en)
|
2005-02-01 |
2006-08-03 |
Amgen Inc. |
Compositions and methods of treating fibrotic disorders
|
|
WO2006128141A2
(en)
|
2005-05-27 |
2006-11-30 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of stromal cell-derived factor-1 (sdf-1) gene expression using short interfering nucleic acid (sina)
|
|
WO2007030167A1
(en)
|
2005-09-02 |
2007-03-15 |
Nastech Pharmaceutical Company Inc. |
Modification of double-stranded ribonucleic acid molecules
|
|
WO2007050643A2
(en)
|
2005-10-24 |
2007-05-03 |
University Of Massachusetts |
Compositions and their uses for gene therapy of bone conditions
|
|
CN101300033A
(zh)
|
2005-11-07 |
2008-11-05 |
泰坦医药品公司 |
用镓对不良肝脏病症的治疗和预防
|
|
FR2894582B1
(fr)
|
2005-12-12 |
2008-02-22 |
Fabre Pierre Dermo Cosmetique |
Sirna anti myosine va et depigmentation de la peau
|
|
AU2006325030B2
(en)
*
|
2005-12-16 |
2012-07-26 |
Cellectis |
Cell penetrating peptide conjugates for delivering nucleic acids into cells
|
|
JP2009522303A
(ja)
|
2005-12-30 |
2009-06-11 |
ウェイ−ウー ヒー， |
瘢痕を生じない皮膚創傷治癒を促進するｓｉＲＮＡ組成物および創傷処置の方法
|
|
US7825099B2
(en)
*
|
2006-01-20 |
2010-11-02 |
Quark Pharmaceuticals, Inc. |
Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
|
|
CN101374528A
(zh)
*
|
2006-01-20 |
2009-02-25 |
夸克医药公司 |
Rtp801的治疗用途
|
|
JP2009523823A
(ja)
|
2006-01-23 |
2009-06-25 |
アボット・ラボラトリーズ |
ｓｉＲＮＡ送達のための化学的に修飾されたポリカチオンポリマー
|
|
CA2638906A1
(en)
|
2006-01-26 |
2007-08-16 |
University Of Massachusetts |
Rna interference agents for therapeutic use
|
|
AU2007349198A1
(en)
|
2006-03-09 |
2008-10-23 |
University Of Rochester |
Peripheral and neural inflammatory crosstalk
|
|
US8163708B2
(en)
|
2006-04-03 |
2012-04-24 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotide
|
|
WO2007136989A2
(en)
|
2006-05-05 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating expression of dgat2
|
|
SI2040725T1
(sl)
|
2006-06-23 |
2014-08-29 |
Engeneic Molecular Delivery Pty Ltd. |
Usmerjene pošiljke zdravil, terapevtskih nukleinskih kislin in funkcionalnih nukleinskih kislin, celicam sesalcev preko intaktnih ubitih bakterijskih celic
|
|
US20080039415A1
(en)
|
2006-08-11 |
2008-02-14 |
Gregory Robert Stewart |
Retrograde transport of sirna and therapeutic uses to treat neurologic disorders
|
|
BRPI0715375A2
(pt)
|
2006-08-18 |
2013-06-18 |
Hoffmann La Roche |
policonjugados para distribuiÇço in vivo de polinucleotÍdeos
|
|
EP2064223B1
(en)
|
2006-09-22 |
2013-04-24 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
|
JP2010507387A
(ja)
|
2006-10-25 |
2010-03-11 |
クアーク・ファーマスーティカルス、インコーポレイテッド |
新規のｓｉＲＮＡおよびその使用方法
|
|
US20080193443A1
(en)
|
2006-10-30 |
2008-08-14 |
Oxana Beskrovnaya |
Methods and compositions for the treatment of polycystic diseases
|
|
US8039010B2
(en)
|
2006-11-03 |
2011-10-18 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
|
|
US20090010948A1
(en)
|
2006-12-15 |
2009-01-08 |
The University Of Hong Kong |
Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
|
|
WO2008109353A1
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting map2k gene expression and uses thereof
|
|
WO2008109105A2
(en)
|
2007-03-06 |
2008-09-12 |
Flagship Ventures |
Methods and compositions for improved therapeutic effects with sirna
|
|
CA2692320A1
(en)
|
2007-07-02 |
2009-01-08 |
Wyeth |
Methods of treating bone disorders with modulators of axl
|
|
US9884899B2
(en)
|
2007-07-06 |
2018-02-06 |
Promedior, Inc. |
Methods for treating fibrosis using CRP antagonists
|
|
WO2009020344A2
(en)
|
2007-08-06 |
2009-02-12 |
Postech Acad Ind Found |
Small interfering rnas (sirnas) controlling multiple target genes and method for preparing the same
|
|
US20090043367A1
(en)
|
2007-08-09 |
2009-02-12 |
Yitzhak Zilberman |
Apparatus and methods for removing an electronic implant from a body
|
|
CA2697043A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Virginia Commonwealth University Intellectual Property Foundation |
Methods and compositions for treatment or prevention of radiation-induced fibrosis
|
|
ES2873350T3
(es)
|
2007-08-27 |
2021-11-03 |
1Globe Health Inst Llc |
Composiciones de ARN interferente asimétrico y usos de las mismas
|
|
US20090131360A1
(en)
|
2007-10-02 |
2009-05-21 |
Rxi Pharmaceuticals, Corp. |
Tripartite RNAi constructs
|
|
CN101809927B
(zh)
*
|
2007-10-02 |
2017-01-18 |
爱立信电话股份有限公司 |
电信系统中的方法和装置
|
|
CA2701845A1
(en)
|
2007-10-03 |
2009-04-09 |
Quark Pharmaceuticals, Inc. |
Novel sirna structures
|
|
EP3705125B1
(en)
|
2007-12-04 |
2023-07-05 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
KR100949791B1
(ko)
|
2007-12-18 |
2010-03-30 |
이동기 |
오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
|
|
EP2245039A4
(en)
|
2008-01-31 |
2012-06-06 |
Alnylam Pharmaceuticals Inc |
OPTIMIZED METHODS FOR EXPORING DSRNA TO TARGET THE PCSK9 GEN
|
|
EP3643782A1
(en)
|
2008-02-11 |
2020-04-29 |
Phio Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
|
EP2268811A1
(en)
|
2008-03-07 |
2011-01-05 |
Santaris Pharma A/S |
Pharmaceutical compositions for treatment of microrna related diseases
|
|
AU2009234266B2
(en)
|
2008-04-11 |
2015-08-06 |
Tekmira Pharmaceuticals Corporation |
Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
|
|
US20110218334A1
(en)
|
2008-07-11 |
2011-09-08 |
Alnylam Pharmaceuticals, Inc. |
PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS
|
|
CN102089429A
(zh)
*
|
2008-07-15 |
2011-06-08 |
弗·哈夫曼-拉罗切有限公司 |
用于抑制TGF-β受体基因表达的组合物和方法
|
|
WO2010008582A2
(en)
|
2008-07-18 |
2010-01-21 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell drug delivery system
|
|
WO2010011346A1
(en)
|
2008-07-24 |
2010-01-28 |
Rxi Pharmaceuticals Corporation |
Rnai constructs and uses therof
|
|
US8946172B2
(en)
|
2008-08-25 |
2015-02-03 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to CTGF
|
|
WO2010027831A1
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Method for reducing scarring during wound healing using antisense compounds directed to ctgf
|
|
WO2010027830A2
(en)
|
2008-08-25 |
2010-03-11 |
Excaliard Pharmaceuticals, Inc. |
Methods for modulation of connective tissue growth factor expression by administering antisense oligonucleotides through a delivery system so as to reduce scarring from wound healing and threat fibrotic diseases
|
|
EP2331141B1
(en)
|
2008-08-25 |
2016-01-06 |
Excaliard Pharmaceuticals, Inc. |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
|
CN108165548B
(zh)
|
2008-09-22 |
2022-10-14 |
菲奥医药公司 |
减小大小的自递送RNAi化合物
|
|
EP2346883B1
(en)
|
2008-09-23 |
2016-03-23 |
Scott G. Petersen |
Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
|
|
WO2010036962A1
(en)
*
|
2008-09-25 |
2010-04-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene
|
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
US9745574B2
(en)
|
2009-02-04 |
2017-08-29 |
Rxi Pharmaceuticals Corporation |
RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
|
US8486909B2
(en)
|
2009-06-24 |
2013-07-16 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
|
|
US20120277158A1
(en)
|
2009-10-06 |
2012-11-01 |
Angiochem Inc. |
Compositions and methods for the transport of therapeutic agents
|
|
US20110268761A1
(en)
|
2010-03-02 |
2011-11-03 |
Hapten Pharmaceuticals, Llc |
Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition
|
|
WO2011109698A1
(en)
|
2010-03-04 |
2011-09-09 |
Rxi Pharmaceuticals Corporation |
Formulations and methods for targeted delivery to phagocyte cells
|
|
CN103200945B
(zh)
|
2010-03-24 |
2016-07-06 |
雷克西制药公司 |
眼部症候中的rna干扰
|
|
KR102453078B1
(ko)
|
2010-03-24 |
2022-10-11 |
피오 파마슈티칼스 코프. |
진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
|
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
|
MX365647B
(es)
|
2011-02-02 |
2019-06-10 |
Excaliard Pharmaceuticals Inc |
El uso de compuestos antisentido dirigidos al factor de crecimiento del tejido conectivo (ctgf) para tratar queloides o cicatrices hipertroficas.
|
|
US20140072613A1
(en)
|
2012-09-10 |
2014-03-13 |
Cynthia Lander |
Compositions and Methods for Treating Cutaneous Scarring
|
|
CN113151180A
(zh)
|
2013-12-02 |
2021-07-23 |
菲奥医药公司 |
癌症的免疫治疗
|
|
CN105960265A
(zh)
|
2013-12-04 |
2016-09-21 |
阿克赛医药公司 |
利用经化学修饰的寡核苷酸处理伤口愈合的方法
|
|
CA2947270A1
(en)
|
2014-04-28 |
2015-11-05 |
Rxi Pharmaceuticals Corporation |
Methods for treating cancer using nucleic acids targeting mdm2 or mycn
|
|
EP3137118A4
(en)
|
2014-05-01 |
2017-11-22 |
RXi Pharmaceuticals Corporation |
Methods for treatment of disorders in the front of the eye utilizing nucleic acid molecules
|
|
KR102689262B1
(ko)
|
2014-09-05 |
2024-07-30 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
|
JP2018502837A
(ja)
|
2014-12-03 |
2018-02-01 |
アールエックスアイ ファーマシューティカルズ コーポレーション |
遺伝子調節アプローチを用いた円形脱毛症の処置方法
|
|
CN116004624A
(zh)
|
2015-04-03 |
2023-04-25 |
马萨诸塞大学 |
用于靶向亨廷汀mRNA的寡核苷酸化合物
|
|
PT3277815T
(pt)
|
2015-04-03 |
2021-11-11 |
Beth Israel Deaconess Medical Ct Inc |
Compostos de oligonucleótidos para o tratamento de pré-eclâmpsia e outros distúrbios angiogénicos
|
|
WO2016161388A1
(en)
|
2015-04-03 |
2016-10-06 |
University Of Massachusetts |
Fully stabilized asymmetric sirna
|
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
|
EP3862005A1
(en)
|
2015-07-06 |
2021-08-11 |
Phio Pharmaceuticals Corp. |
Nucleic acid molecules targeting superoxide dismutase 1 (sod1)
|
|
CA2997949A1
(en)
|
2015-09-11 |
2017-03-16 |
Rxi Pharmaceuticals Corporation |
Methods for treating skin disorders and conditions utilizing haptens
|
|
AU2016322934A1
(en)
|
2015-09-14 |
2018-04-12 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta
|
|
US11021707B2
(en)
|
2015-10-19 |
2021-06-01 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA
|
|
WO2018195355A1
(en)
|
2017-04-19 |
2018-10-25 |
Rxi Pharmaceuticals Corporation |
Topical delivery of nucleic acid compounds
|